INS and type 2 diabetes mellitus: Improvement in insulin sensitivity in obesity and T2D-associated NAFLD have been achieved using lipid metabolism-modifying agents like ketohexokinase inhibitor, a protein tyrosine phosphatase-1B inhibitor, or an ω3-fatty acid [reviewed in (117)].